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Abstract 
 
Activation-induced cytidine deaminase (AID) is a key protein required for both 
class switch recombination (CSR) and somatic hypermutation (SHM) of antibody 
genes.  AID is induced in B cells during an immune response.  Lack of AID or 
mutant form of AID causes immunodeficiency; e.g., various mutations in the C 
terminus of AID causes hyper IgM (HIGM2) syndrome in humans. The C terminal 
10 amino acids of AID are required for CSR but not for SHM.  During both CSR 
and SHM, AID deaminates dCs within Ig genes, converting them to dUs, which 
are then either replicated over, creating mutations, or excised by uracil DNA 
glycosylase (UNG), leading to DNA breaks in Ig switch regions.  Also, the 
mismatch repair (MMR) heterodimer Msh2-Msh6 recognizes U:G mismatches 
resulting from AID activity and initiates MMR, which leads to increased switch 
region double strand breaks (DSBs).  DSBs are essential intermediates of CSR; 
lack of UNG or MMR results in a reduction of DSBs and CSR.  The DSBs 
created in the Sµ and one of the downstream S-regions during CSR are 
recombined by non-homologous end joining (NHEJ) to complete CSR.  Available 
data suggest that AID is required not only for the deamination step of CSR, but 
also for one or more of the steps of CSR that are downstream of deamination 
step.  This study investigates the role of C terminus of AID in CSR steps 
downstream of deamination.  
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Using retroviral transduction into mouse splenic B cells, I show that AID binds 
cooperatively with UNG and Msh2-Msh6 to the Ig Sµ region, and this depends on 
the AID C terminus.  I also show that the function of MMR during CSR depends 
on the AID C terminus.  Surprisingly, the C terminus of AID is not required for Sµ 
or Sγ3 DSBs, suggesting its role in CSR occurs during repair and/or 
recombination of DSBs.    
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Chapter I 
INTRODUCTION 
 
When naïve B cells are activated via infection or immunization, they switch 
immunoglobulin (Ig) heavy chain isotypes, from initial expression of IgM and IgD 
to expression of IgG, IgE, or IgA, which alters the effector functions of the 
antibodies.  Isotype switching occurs by class switch recombination (CSR), a 
unique intrachromosomal (mostly) DNA recombination, which involves 
introduction of double-strand breaks (DSBs) into special DNA regions, termed 
switch (S) regions, which range from 1 to 12 kb in length, and are located directly 
upstream of each constant region (C) gene of the Igh locus (1).  During B cell 
activation, single nucleotide mutations are also introduced into antibody variable 
regions in a process called somatic hypermutation (SHM).   
 
Activation-induced cytidine deaminase (AID) initiates CSR and SHM.  AID 
deaminates dCs to dUs, preferentially in WRC motifs (where W = A or T; R = G 
or A) (2-5). These motifs are very abundant in S region DNA.  During CSR, the 
dUs created by AID activity at S regions are converted into DSBs in the donor 
(Sµ) and acceptor Sx regions, which are then recombined typically by non-
homologous end joining (NHEJ), and the intervening sequence is removed as a 
circular product (Fig 1).   
  2 
  
Figure 1
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Figure 1 CSR model. Igh locus showing constant region genes for IgM, IgD, 
IgG3, IgG1, IgG2b, IgG2a, IgE and IgA after a VDJ recombination. Each C-
region is preceded by an S-region, where transcription takes place to generate 
AID substrates, which also generates germline transcripts: Sµ though Cµ, Sµ 
though Cδ, and Sε through Cε (in this particular case). AID induces DSBs in the 
S –regions; which S-region depends on the mode of activation. The DSB on Sµ 
and one of the downstream Sx region are then joined by NHEJ. The intervening 
sequence is removed as a circular product. On this figure, the end result is 
switching to IgE (1).
  4 
 
Double-strand break formation during CSR 
The dUs generated during CSR and SHM on S regions and V genes, 
respectively, are removed by uracil-N-glycosylase2 (UNG).  Deficiency in UNG 
results in a dramatic reduction in CSR, chromosomal translocations between the 
IgH and c-myc loci, and causes a dramatic increase in G>A and C>T transition 
mutations during SHM as DNA is replicated without UNG being removed (6-9).  
Apurinic-apyrimidinic endonuclease 1 and 2 (APE1/2) have been shown to be 
important for DSB formation during CSR (10), presumably due to their ability to 
nick the abasic sites generated by UNG activity during CSR.  If the nicked sites 
on opposite strands are sufficiently near, they can spontaneously form DSBs that 
are substrates for NHEJ (Fig 2).   
 
On the other hand, AID generated G:U mismatches are also substrates for 
mismatch repair proteins (MMR). If the single stranded nicks on opposite DNA 
strands, generated by AID-UNG-APE activities, are too far apart, MMR proteins 
can process the single-stranded nicks into DSBs during CSR (10-12). The (MutS 
homologues) Msh2-Msh6 heterodimer can bind to G:U mismatches, then recruit 
Mlh1-Pms2 heterodimers (13, 14).  Binding of these MMR proteins to the 
mismatch promotes loading of Exonuclease 1 (Exo1) (15) at the SSBs that are 
generated by APE1/2 activity. Exo1 can continue excision past the U:G mismatch 
until reaching a SSB on the other DNA strand, thus creating a DSB with 
staggered ends. A DNA polymerase can then fill in the staggered end to 
  5 
generate a blunt or nearly blunt-ended DSB (11) (Fig 3).. If the nearest SSB is 
located 3’ to the U:G mismatch, the nicking activity of Pms2 is required to create 
a SSB 5’ to the mismatch in order for Exo1 to be able to excise it (16, 17).  
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Figure 2 
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Figure 2 AID is required for both CSR and SHM.  AID deaminates dCs to dUs 
during CSR and SHM. During SHM, the dUs can be replicated to produce G:C to 
A:T transition mutations, which is termed as phase-I(A) of SHM; or the dUs can 
be removed by UNG. The abasic site can be replicated to produce 
transition/transversion mutations, which is termed as phase-I(B) of SHM (18).  
The abasic site can also be nicked by AP endonuclease, an error prone 
polymerase such as polymerase η can introduce a patch with mutations at  A:T 
base pairs via strand-displacement reaction (19), this is termed as phase-II of 
SHM. During CSR, some of these nicks are eventually converted into DSBs.
  8 
 
Figure 3 
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Figure 3 MMR model for DSB formation during CSR. The Msh2-Msh6 
heterodimer can bind to the U:G mismatch and recruit Exo I to a nicked site 
located 5’ side of the U:G mismatch. The Exo I can remove a patch of DNA until 
it reached the nicked site on the other strand.  A DNA polymerase then fills in the 
staggered end of the DNA to generate a DSB (1). 
  10 
 
SHM 
Unlike CSR, SHM induces single amino acid mutations, most frequently at the 
antigen recognition sites of antibodies (complementarity determining regions, 
CDRs), which can enhance the ability of an antibody to bind antigens (20-22).  
During SHM, error prone polymerases can replicate DNA through the abasic 
sites created by UNG activity to generate transition and transversion mutations 
(8, 18). At the same time, the DNA with dUs can be replicated to generate G>A 
and C>T transition mutations. In ung-/- mice, G:C mutations are severely skewed 
towards G>A and C>T transition mutations, while the A:T mutations are similar in 
both ung-/- and WT mice (6, 7, 23). Hence, the AID and UNG activities at G:C 
base pairs generate the first phase of SHM as postulated by Petersen-Mahrt, S 
et al (18) (Fig 2).   
 
In the second phase of SHM, G:U mismatches induced by AID can be 
recognized by the mismatch repair proteins, Msh2 and Msh6 heterodimer (21).  
As described above, this will in turn recruit MutL homologues (Mlh1 and Pms2 
heterodimer), and Exo1 to the mismatch. Mice deficient in Msh2 (24-26) or Msh6 
(27-29) show very few A:T mutations in V regions in mice.  Interestingly, it has 
been also shown that msh6-/- mice have an altered targeting of AID, where the 
AID induced mutations in V regions are more focused to the AID target 
WRC/GYW hotspots (28, 30). Hence, actions of AID and MMR are very 
important to generate mutations at both G:C and A:T base pairs during the 
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second phase of SHM, and MMR proteins have a role in not only steps 
downstream of AID activity, but also in targeting of AID itself. 
 
AID protein and deamination activity 
Mouse AID is a 198 amino acid, 24 kD protein; mouse AID has 92% homology to 
human AID (31).  AID has a putative nuclear localization signal at the N-terminus 
between amino acids 9 and 26 (32), a SHM domain between amino acids 13 and 
23 (33), a catalytic (deaminase) domain between amino acids 56 and 94, and a 
domain required for CSR, but not SHM, between amino acids 182 and 198 (34-
37). It also has a nuclear export signal (NES) at the C-terminus between amino 
acids 190 and 198 (32, 38, 39) (Fig 4).  
 
AID has been shown to preferentially deaminate dCs to dUs in WRC motifs on 
single stranded DNA in vitro (2-5, 40, 41).  Transcription through S regions is a 
prerequisite for CSR, apparently due to the ability of transcription to generate 
single stranded (ss) DNA (42, 43), the substrate for AID (3, 4, 44, 45).  Also, AID 
interacts with RNA polymerase II (RNPII), suggesting that AID targeting (46) to 
the Ig locus is linked to the transcription complex during CSR and SHM (47). 
Transcription also induces histone modifications that might increase accessibility 
of the DNA to AID (48, 49). 
 
  12 
According to in vitro experiments, AID has a higher activity when it is in a higher 
order oligomeric form (50).  The dimerization domain of AID is unknown, but C-
terminus truncated AID (last 10 amino acids) (ΔAID) can still form an oligomer.  
Also, human patients heterozygous for Δ AID present with HIGM2 syndrome, 
indicating that ΔAID might have a dominant negative effect (36, 51).  It is also 
important to note that these patients have normal SHM levels (36, 51). 
  13 
 
 
 
 
Figure 4  
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Figure 4 Schematic representation of the structure of AID; NLS (nuclear 
localization signal) domain, SHM (somatic hypermutation) domain, 
catalytic/deamination domain, CSR (class switch recombination) domain, and 
NES (nuclear export signal) domain. Last 10 amino acids in the C-terminus of 
AID are required for CSR but not SHM.   
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Regulation of AID  
Although AID is essential for CSR and SHM, tight regulation of AID activity is 
imperative as AID activity is potentially highly genotoxic. Recent developments 
suggest that although AID is expressed predominantly in germinal center B cells, 
it is expressed in a variety of other tissues at much lower levels as well (52, 53).  
Mouse models constitutively expressing AID are prone to developing tumors, e.g. 
lung tumors and T-cell lymphomas (54, 55).  However, a transgenic mouse 
model with AID expression driven by the CD19 promoter does not develop B cell 
lymphomas (56), suggesting that B cells negatively regulate AID. In addition, AID 
has been implicated in causing c-myc and Igh translocations similar to those in 
lymphomas (9, 57, 58).  Although the ability of AID to deaminate dCs only on 
ssDNA appears to limit its activity to transcribed genes, it might induce DNA 
lesions in an array of non-Ig genes transcribed during CSR.  
 
Transcriptional regulation of AID 
AID expression in B cells is induced by the same signals that activate B cells to 
undergo CSR.  In vitro, AID is expressed in mouse B cells 48 hours after cytokine 
activation (42). The AID genetic locus (aicda) has four regions that are found to 
be important for transcriptional regulation, a 1.5 kb promoter with NF-κB, STAT6, 
HoxC4, Sp1 and Pax5 binding sites, but no TATA box (59-62). Signal 
transduction pathways such as JAK/STAT and signals downstream of NF-κB 
have been shown to be involved in AID expression in B cells (61, 63).  E47, an E-
  16 
protein, a helix-loop-helix transcription factor, can activate the intronic enhancer 
in the aicda gene to induce AID expression in B cells (60).  Blimp1, a 
transcription factor involved in plasma cell differentiation, which occurs after CSR 
and SHM, inhibits the expression of the transcription factor Pax5 (64), as well as 
AID (65).  Also, interferon regulatory factor (IRF-4), which inhibits Blimp-1 
transcription, increases AID expression (66, 67).  
 
Post-transcriptional/post-translational regulation of AID 
AID is post-transcriptionally negatively regulated at the mRNA level by the 
lymphocyte specific micro-RNAs, miR-155 and miR-181b (68-70).   Also, post-
translational modification of nuclear AID at Ser38 via phosphorylation was shown 
to be important for both CSR and SHM (71-74).  AID protein level in the nucleus 
of B cells itself is limited, and AID is suggested to have a weak nuclear 
localization signal (NLS) on its N-terminal domain (32, 38, 39). By contrast, the 
C-terminus of AID has a robust nuclear export signal (NES) dependent upon 
chromosome region maintenance-1 (CRM1) protein (39). Hence, AID protein 
predominantly resides in the cytoplasm (75). Although the C terminus of AID is 
also required for CSR, nuclear export is not required for CSR, as mouse AIDF198A 
is not exported from nuclei, and yet CSR and SHM are only modestly reduced in 
cells expressing this mutant (39). Therefore, restrictive concentration of AID 
protein in the nucleus by weak nuclear localization and CRM1-mediated nuclear 
export of AID has been suggested to curb AID induced lesions in non-Ig loci (39).  
  17 
 
The activity of AID seems to be further limited by enhanced ubiquitin-mediated 
degradation of nuclear AID.  The half-life of nuclear AID is shorter, approximately 
three times less than that of cytoplasmic AID (76). However, since patients 
heterozygous or homozygous for mutations in the NES of AID have no change in 
AID-induced mutation frequencies (34, 36, 51), this indicates that lengthening the 
life span of nuclear AID does not increase mutagenesis.  Although ubiquitin-
mediated proteasomal degradation of AID is not fast enough to completely shut 
down AID deamination activity, it might prevent AID protein from carrying out 
steps downstream of deamination during CSR in Igh locus such as deletion 
recombination (CSR like event) in non-Ig loci . Hence, ubiquitin-mediated 
proteasomal degradation of AID might help to fine-tune AID regulation by 
reducing the concentration AID protein in the nucleus. 
 
AID is involved in protein-protein interactions 
It has been suggested that protein-protein interactions are important for AID to 
perform CSR, because several AID mutants have defects in CSR, in particular, 
some with the mutations in NES are unable to retain CSR while they retain SHM 
(34, 76, 77). Hence, the ability of AID to form a CSR specific complex via protein-
protein interaction might be another layer of protection from AID induced 
genomic modification such as inter-gene recombination to prevent translocations 
or harmful deletion of genes/parts of genes. 
  18 
AID has been shown to interact with numerous proteins, but no CSR specific or 
SHM specific factor that interacts with AID has been published yet, except for 14-
3-3 adaptor protein and DNA-dependent protein kinase catalytic subunit (DNA-
PKcs).  A recent publication reported that the C-terminus of AID interacts with the 
14-3-3 adaptor protein complex and that this interaction is important for 
recruitment of AID to S regions (78).  Deficiency in 14-3-3 protein components 
results in a 50% decrease in CSR.  DNA-PKcs has been shown to interact with 
the C-terminus of AID in a DNA dependent manner (79).  Although DNA-PKcs 
has been suggested to be important for joining AID dependent DSBs in Igh locus 
(80), DNA-PKcs deficient mice have not consistently shown impairment in CSR. 
AID has also been shown to interact with Spt5, thereby bringing AID to sites of 
RNPII stalling (81).  Also, AID interacts with RNA polymerase II (RNPII), 
suggesting that AID targeting to the Igh locus is linked to the transcription 
complex during CSR and SHM (47). This raises more questions because AID-
RNPII interaction does not provide Igh locus specificity for AID; instead it might 
make all the genes transcribed in activated B cells vulnerable to AID activity.  It 
has also been shown that AID interacts with CTNNBL1, a component of the RNA 
splicing complex.  CTNNBL1 is suggested to be one of the AID interacting 
proteins that might be involved in targeting of AID to the Igh locus (82).  
However, deletion of this protein does not affect CSR (83).  Another protein, 
MDM2, an oncoprotein, which targets p53 for nuclear export and degradation, 
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was shown to interact with the C-terminus of AID, but MDM2 is not important for 
antibody diversification (84).  
 
The regulatory and catalytic subunit of protein kinase A (PKA), which 
phosphorylates AID at S38, is specifically localized in S region DNA during CSR, 
and might participate in a PKA-RPA-AID complex (85).  Phosphorylation of S38 
on AID is not required for S region binding of AID but it is required for CSR; 
phosphorylation of S38 does promote interaction between AID and Replication 
Protein A32 (RPA32), which enhances the DNA binding property of AID, and also 
its deaminase activity (71, 86).  Hence, it is suggested that PKA causes localized 
phosphorylation of AID and nucleates a CSR-specific complex on the S region 
(85). Such a CSR-specific complex might be important for promoting  
acceptor/donor S-region DNA synapses and/or facilitating NHEJ, making these 
processes mediated by AID associated with S-region DNA.  
 
The C-terminus of AID is important for CSR 
Some of the NES mutants that are unable to support CSR are still able to 
perform SHM of Ig V regions (34, 76, 77). For example, mouse B cells 
expressing ΔAID (last 10 amino acids deleted) have greatly reduced CSR (~10% 
of WT), but retain normal levels of SHM and AID-induced mutations in the Sµ 
region (34).  Although the mutation frequencies in the Sµ region are unaltered in 
ΔAID expressing B cells, G>A and C>T transition mutations are increased by two 
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fold compared to that of WT AID expressing B cells (34), which is similar to the 
effect of UNG deficiency on SHM (6). Hence, lack of C-terminus of AID prevents 
CSR and alters the AID induced mutation pattern in Sµ region. 
 
 Also it is important to note that the NES mutant AID (last 17 amino acids 
deleted) appears to be more catalytically active than full length AID in vitro (87), 
and ΔAID (AIDΔ189-198) has been shown to be at least as catalytically active as full 
length AID (34).  If this is true in vivo also, it is clear that the deamination activity 
of AID is not adequate to complete CSR, which also requires additional AID-C-
terminus-mediated events.  
 
Hypothesis  
The lack of the AID C-terminus compromises the efficiency of UNG activity 
during CSR. Interestingly, RPA32, which interacts with the phosphorylated form 
of AID, has been shown to interact with UNG by the yeast two-hybrid assay (88). 
It has been found that msh6-/- mice have altered targeting of AID, as the AID 
induced-mutations in V regions are more focused at WRC hotspots in these mice 
than in WT mice (28, 30). These facts support the idea that AID might exist in a 
complex with UNG and MMR proteins. Such a complex might cause AID-induced 
mutations to more efficiently lead to CSR.  
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Our results support my hypothesis that AID interacts with UNG and MMR in an 
AID-C-terminus dependent manner when associated with the Ig Sµ region. This 
interaction increases the binding of AID, UNG, and Msh2-Msh6 to Sµ, and this 
interaction is functionally important for CSR.   
 
Our fundamental experimental approach involved isolation of mouse splenic B 
cells by T cell depletion using anti-T cell antibody and complement. We cultures 
the B cells for two days in complete medium.  We perform retroviral transduction 
on day two to express AID-ER, ΔAID-ER, or ER. We performed experiments on 
these cells 24 hours after retroviral transduction (fig 5). 
  22 
 
Figure 5
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Figure 5 Experimental Approach. mouse splenic B cells are purified by T cell 
depletion using anti-T cell antibody and complement. The B cells were then 
cultured for two days in a complete medium.  We perform retroviral transduction 
on day two to express AID-ER, ΔAID-ER, or ER in the cultured cells.  The cells 
were then put back in culture in presence of 4OHT for one more day.  One day 
after the retroviral transduction, cells were prepared for FACS analysis or the live 
cells were purified using Ficoll gradient.  The live cells were crossed-linked (X-L) 
for ChIP analysis, DNA extraction was done to perform LM-PCR, or cell extracts 
were made for IP and/or western blot.  
  24 
Chapter II 
MATERIALS AND METHODS 
 
Mice. All mouse strains were extensively (eight generations) backcrossed to 
C75BL/6. AID-deficient mice were obtained from T. Honjo (Kyoto University, 
Kyoto, Japan) (89). Msh2-deficient mice were obtained from T. Mak, Univ. of 
Toronto CA (90). Mlh1-deficient mice were obtained from R.M. Liskay, Oregon 
Health Sciences University, Portland OR (91).  UNG-deficient mice were 
obtained from D. Barnes and T. Lindahl, London Research Institute, UK (92).  
Msh6-deficient mice were obtained from W. Edelmann (93). Double knockout 
mice were bred by mating heterozygous mice. Mice were housed in the 
Institutional Animal Care and Use Committee-approved specific pathogen-free 
facility at the University of Massachusetts Medical School; these mice were used 
according to the guidelines from University of Massachusetts Medical School 
Animal Care and Use committee. For each experiment, splenic B cells were 
isolated from littermates. 
 
Antibodies.  Primary antibodies were for: ER (Santa Cruz Biotechnology sc-
8002, lots G2307 and D0110); UNG (rabbit anti-peptide amino acids 280-295 
from mouse UNG, prepared by Anaspec Corp); MSH2 (sc-494), MSH6 (sc-
10798), and GAPDH (sc-25778).  For immunoblotting, secondary antibodies 
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used were goat-anti-rabbit (sc-2004) or donkey anti-mouse-horseradish 
peroxidase (sc-2020)(all from Santa Cruz Biotechnology). 
 
Retroviral constructs.  pMX-PIE-AID-FLAG-ER-IRES-GFP-puro and pMX-PIE-
ΔAID-FLAG-ER-IRES-GFP-puro (34) were received from Drs V. Barretto and M. 
Nussenzweig (The Rockefeller University, NY).  To create the control retrovirus: 
pMX-PIE-ER-IRES-GFP, the ER gene from RV-AID-ER was PCR amplified with 
a forward primer: 5’ GCCGGATCCCGCCATGTCTGCTGGAGACATGAGAGCT 
3’; and a reverse primer: 5’ 
GGCCTCGAGGAGCTCAAGCTGTGGCAGGGAAACC 3’.  The PCR product 
was digested with BamHI and XhoI, and inserted into BamHI- and XhoI-digested 
pMX-PIE vector containing IRES, GFP, and puromycin genes downstream of 
XhoI site.  The construct was sequenced and we confirmed proper expression of 
the RV-ER construct by western blotting.   
 
B cell purification and cultures.  Mouse splenic B cells were isolated as 
previously described, by T cell depletion with antibody and complement (94).  B 
cells were cultured at 105 cells/ml in 5% CO2.  Lipopolysaccharide (LPS) (50 
µg/ml), anti-IgD dextran (α−δ-dex) (0.3 ng/ml) and IL-4 (20 ng/ml) were used to 
induce class switch recombination to IgG1; LPS and α-δ-dex were used to induce 
IgG3 switching.  Human BAFF/BLyS (50 ng/ml)(Human Genome Sciences) was 
included in all cultures.   
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Cell cycle analysis.  To analyze cell cycle progression of cells expressing AID-
ER, ΔAID -ER, or ER, aid-/- mouse splenic B cells were transduced with 
retroviruses after culture for 48 hours.  Cells were harvested one day later, and 
flow cytometry was used to determine GFP expression levels. Cells were stained 
with PI and analyzed by flow cytometry to study the cell cycle progression. For 
this experiment we used cultures in which more than 95% of cells expressed 
GFP.   
 
Cell proliferation assay.  Proliferation of aid-/- B cells expressing AID-ER, 
ΔAID-ER, or ER was assayed by staining freshly isolated aid-/- mouse splenic B 
cells with PKH26 (Sigma), which stains the cell membrane, as prescribed in the 
product manual.  Cells were then cultured for 48 hours, and infected with 
retroviruses expressing AID-ER, ΔAID -ER, or ER.  PKH26 fluorescence was 
assayed by live cell FACS two days after infection.   
 
Production of retroviruses in Phoenix-E cells. 
We seeded 3x106 Phoenix-E cells per 10 cm plate 24 hrs before transfection with 
the retroviral constructs in 10 ml of complete RPMI1640 medium (10% heat-
inactivated serum, 100 µg/ml penicillin- streptomycin, 2 mM L-glutamine, 5 ml 
non-essential amino-acids (GIBCO 11140), 1 mM sodium pyruvate (GIBCO), 5 
ml of 100XBME (β-mercaptoethanol)). 100XBME was made by adding 35µL of 
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concentrated BME and 1 ml fetal bovine serum in 99ml of 1XPBS.  To transfect 
the retroviral constructs, Fugene 6 (Roche) was brought to room-temp and mixed 
well before use.  27 µ L of Fugene 6 was added to 600 µ L of serum free 
RPMI1640 at room temperature. Fugene 6 was pipetted directly into the medium 
without contacting the walls of the plastic tube, mixed, and incubated at room-
temperature for 5 min. Six µg of retroviral plasmid construct and 3 µg pCL-Eco 
plasmid (expressing RV-Gag, Pol, and Env proteins) were added, mixed, and 
incubated for 45 min at room temperature. The mixture was then added drop-
wise to the 10 cm plate containing  Phoenix-E cells, and the culture dish was 
swirled to ensure even distribution of the mixture.  The plate was incubated at 
37°C for 24 hrs, and moved to a 32°C incubator, which resulted in a higher titer 
of virus production (the virus is unstable at higher temperatures).  Twenty-four 
hours after the transfection, the transfection efficiency of Phoenix cells was 
checked by FACS for GFP expression.  Cultures that have ~65-90% GFP+ cells 
yielded good to excellent virus titers.  Virus supernatant was collected 2 days 
after transfection, and replaced with 10 ml of fresh complete RPMI1640 with 
heat-inactivated serum. The supernatant was then centrifuged at 1200 rpm for 5 
min. Virus was harvested 2 more times every 48 hrs thereafter. The supernatant 
was used immediately or snap-frozen in liquid nitrogen before storing at -80°C.  
Since the virus-titer drops by 50% with each freeze-thaw cycle, appropriate 
aliquots were made before they were frozen. 
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Retroviral infection of B cells.  4 ml of B cells at 105 per ml were cultured for 
two days in 6 well plates or 2 ml at 105 per ml in 24-well plates in IgG1 
(LPS+Blys+ anti-δ-dextran+ IL4) or IgG3 (LPS+Blys+ anti-δ-dextran) CSR 
conditions.  Each culture was split into two cultures on day 2.  The split culture 
plates were centrifuged at 1200 rpm for 5 min after the split in order to remove 
the supernatant without removing the cells.  The cells on the plate were re-
suspended in the retrovirus cocktail containing: virus supernatant 1 ml, 
RPMI1640 1ml, heat-inactivated FBS 30 µL, LPS (50 µg/ml), IL4 (20 ng/ml) (not 
included in IgG3 switching conditions), BLyS (50 ng/ml), anti-δ-dex (0.3 ng/ml), 
4OHT (Sigma) (1 µM) (34) and polybrene (10 µg/mL)  (34). After incubating the 
cocktail for 45 min at room temp, the cells were resuspended in the cocktail and 
the culture plates were centrifuged at 2000 rpm (Beckman-Coulter, Allegra-12R 
centrifuge) for 45 minutes at 20°C.  The plates were returned to 37°C, 5% CO2 
for 24 hrs, and flow-cytometric analysis was done to check GFP expression level 
and CSR assay.   
 
CSR Assay and Flow-cytometric analysis.  To study CSR in B cells 
expressing AID-ER, ΔAID-ER, or ER, we cultured 2 ml of B cells (105 per ml) for 
2 days in IgG1 or IgG3 switching conditions described above, and infected these 
cells with retrovirus to express AID-ER, ΔAID-ER, or ER.  The cells were treated 
with 1 µM 4OHT at the time of infection. Cells were harvested 24 hr after 
infection and subjected to (Fluorescence Activated Cell Sorting) FACS staining 
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and analysis was partly done as described previously (94), except that cells were 
also treated with 7-AAD to eliminate dead and dying cells more efficiently.   
Twenty-four hours after the retroviral transduction, cells were washed three times 
with 2 ml of FACS buffer (1XPBS with 2% FBS), each time cells were pelleted by 
centrifuging the tubes at 335Xg at 4°C. Cells were kept in ice at all times. After 
the last wash, cells were resuspended in 50 µL of the FACS buffer. 0.0025 µg/ml 
PE-IgG1 (Southern Biotech) or 0.001 µg/ml PE-IgG3 (Southern Biotech) were 
added to the cell suspension and the tubes were incubated in ice for 30 minutes.  
The stained cells were washed again 3 times with the FACS buffer, and were 
suspended in 400 µL of the FACS buffer after the final wash.  0.8 µg/µl 7-AAD 
(Imgenex) was added to the final cell suspension. 
 
Flow-cytometric analysis was performed using Flowjo software, first 7-AAD 
negative cells were selected to eliminate the dead or dying cells. GFP-positive 
cells were gated within the 7-AAD negative cells.  Then PE-IgG1 or PE-IgG3 
cells were gated within the 7-AAD-negative and GFP-positive cells.    
 
Chromatin immunoprecipitation (ChIP).  ChIP assays were performed as 
described previously (95).  B cells were cultured for 2 days in IgG3 conditions, 
retroviral transduction was done on day two.  The cells were treated with 4OHT 
at the time of retroviral transduction. Live cells were isolated by flotation on 
Lympholyte M (Cedar Lane, Ontario Canada) 24 hours after retroviral 
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transduction.  1 ml of Lympholyte M at room temperature was placed in 15 ml 
Falcon tubes (BD), and overlayed with 8 ml of the cell culture.  The tubes were 
then centrifuged at 1200Xg for 20 minutes at room temperature.  The live cells, 
which float on the top layer of the Lympholyte M were gently removed by a 
pasture-pipette.  The live cells were then washed twice in serum free 1XPBS. 
After the 2nd wash, 2X107 cells were resuspended in 1XPBS and  were cross-
linked with formaldehyde at a final concentration of 1% for 2 min at 37°C. Then 
cross-linking was stopped by adding 125 mM glycine (final concentration) and 
incubating at room temperature for 5 minutes.   
 
The cross-linked cells were washed twice with 1XPBS then lysed in ice for 10 
minutes in lysis buffer (1%SDS, 10 mM EDTA, 50 mM Tri-Cl pH 8.1, 1X EDTA–
free protease inhibitor cocktail (Roche), 10 mM NaF (sodium fluoride), 1 mM 
Na3VO4 (sodiumorthovanadate), 10 µg/ml PMSF (phenylmethanesulfonyl-
fluoride) in distilled water, then sonicated on ice for 3 minutes. Sonication was 
performed in 10 sec bursts, the samples were incubated for 15 seconds in ice 
between each bursts. The cell lysates were precleared with 75 µL 50% pre 
coated protein A/G-agarose beads, rotated end-to-end at 4°C for 2 hours. 106 cell 
equivalents of precleared cell lysate were used per IP, and 105 cells were used 
for the input samples.  To correct for this difference, ChIP results were divided by 
10. Significance was calculated by a two-tailed T test. ChIP results were assayed 
by real time PCR using Sybr Green (Invitrogen).  Primers for Sµ were: (forward) 
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DK99 5’-AAC TAG GCT GGC TTA ACC GAG ATG-3’, (reverse) DK100 5’-GTC 
CAG TGT AGG CAG TAG AGT TTA-3’; Primers for Cµ were: (forward) DK46 5’-
GTC AGT CCT TCC CAA ATG TCT TCC-3’, (reverse) DK47 5’-CTG GAA TGG 
GCA CAT GCA GAT CTT T-3’. 
 
For immunoprecipitation, 25 µl of pre-cleared cell lysate containing 106 cell 
equivalents were added to 1.4 ml dilution buffer. The dilution buffer contained 
distilled water with 0.01% SDS, 1.1% Triton-X 100, 1.2 mM EDTA, 16.7 mM Tris-
Cl pH 8.1, 167 mM NaCl, 1X EDTA–free protease inhibitor cocktail, 10 mM NaF, 
1 mM Na3VO4 , 10 µg/ml PMSF.  Immunoprecipitation was done with 2-8 µg of 
antibody, which was added to the diluted cell lysate and incubated (end-to-end 
rotation) at 4°C over night.  On the following day, 50 µL 50% coated protein A-G 
beads were added to each tube and incubated at 4°C for 2 hours with end-to-end 
rotation.  Then the beads were pelleted by centrifuging at 500Xg. The beads 
were then washed 5 minutes each (end-to-end rotation at 4°C) with low-salt wash 
buffer (0.1% SDS, 1% Triton-X 100, 2 mM EDTA, 20 mM Tris-Cl pH 8.1, 150 mM 
NaCl, 1X EDTA–free protease inhibitor cocktail, 10 mM NaF, 1 mM Na3VO4 , 10 
µg/ml PMSF in distilled water), high-salt wash buffer (0.1% SDS, 1% Triton-X 
100, 2 mM EDTA, 20 mM Tris-Cl pH 8.1, 500 mM NaCl, 1X EDTA–free protease 
inhibitor cocktail, 10 mM NaF, 1 mM Na3VO4 , 10 µg/ml PMSF in distilled water), 
Lithium-salt wash buffer (250 mM LiCl, 1% Deoxycholate, 1% Nonidet P-40, 1 
mM EDTA, 10 mM Tris-Cl pH 8.1 in distilled water), and TE (10 mM Tris-Cl pH 
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8.1, 1 mM EDTA, 1X EDTA–free protease inhibitor cocktail, 10 mM NaF, 1 mM 
Na3VO4 , 10 µg/ml PMSF).  After the final wash, the excess TE was removed as 
much as possible.  The beads were then resuspended in 400 µl of elution buffer 
(10 mM Tris-Cl pH 8.1, 5 mM EDTA, 300 mM NaCl, 0.5% SDS in distilled water), 
and incubated at 65°C over-night.  Then the temperature was reduced to 55°C, 2 
µL 10 mg/ml proteinase K was added and incubated again over-night.  The DNA 
was purified by 2 phenol-chloroform (1:1) extraction followed by ethanol 
precipitation (1 µL of 20 mg/ml glycogen in 1 ml 95% ethanol) over-night at -
20°C.  The precipitated DNA was washed twice with 75% ethanol, and the DNA 
pellet was dried in air.  The dry pellet was then dissolved in 25 µL of the TE 
buffer without protease inhibitors.  The DNA was then analyzed by a real-time 
PCR. The input DNA by prepared by adding 10 µl of the cross-linked cell lysates 
to 400 µl TE without protease inhibitors. 30 µl 5 M NaCl was added and uncross-
linked over-night at 65°C. Then 1 µl of 10 mg/ml RNase and 2 µl 10 mg/ml 
Proteinase K were added and incubated at 55°C over-night.  Then ethanol 
purification of the DNA was done as described above.  Dry input DNA pellet was 
resuspended in 75 µl of the TE buffer without protease inhibitors.  
 
In vitro transcription translation.  The T7 promoter was fused to the AID-ER, 
ΔAID-ER, ER, GST and GST-UNG genes.  The constructs were then inserted 
into pCSR®4-TOPO (Invitrogen) plasmid. In vitro transcription and translation 
were performed using the PROTEINscript® II T7 Kit, as prescribed in the 
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manufacturer’s manual (Ambion).  In vitro transcription and translation was 
optimized for comparable levels of expression of AID-ER, ΔAID-ER, and ER also, 
GST and GST-UNG. 
 
GST Pull-down.  Equal volume of GST or GST-UNG was added to each tube 
containing AID-ER, ΔAID -ER and ER. Dilution buffer containing: 1XPBS with 
Complete protease inhibitor cocktail (Roche; 25X=1 tab/2 ml 1XPBS), 200 µM 
phenylmethanesulfonylfluoride (PMSF), 200 µM sodium orthovanadate, 50 µM 
NaF, 2 µM β -glycerophosphate, 50 µM ZnCl2, 200 µg/ml ethidium bromide was 
added up to the final volume of 500 µL.  The mixtures were incubated at 4°C for 
12 hrs and then incubated with glutathione beads for another 2 hrs.  The beads 
were spun down and then washed 3X with wash buffer. The wash buffer was 
made by adding 200 mM NaCl and 0.05% NP40 to the dilution buffer without 
ethidium bromide. The proteins were then eluted with elution buffer after the third 
wash.  The eluates were then subjected to western blot.  
 
Genomic DNA preparation and linker ligation-mediated PCR (LM-PCR).  
After culture for two days and 24 hours after retroviral transduction, viable cells 
were isolated by flotation on Lympholyte M (Cedar Lane, Ontario, Canada), cells 
were imbedded in low melt agarose plugs, DNA isolated and LM-PCR performed 
as described (42), with slight modifications.  For linker ligation, 50 µL 1X ligase 
buffer was added to the plugs, which were then heated to 62°C to melt the 
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agarose.  20 µL DNA (about 200,000 cell equivalents) was added to 2 µL T4 
DNA Ligase (2 Weiss units, MBI Fermentas, Hanover, MD), 10 µL ds annealed 
linker in 1X ligase buffer, 3 µL 10x Ligase buffer and 30 µL dH20 and incubated 
overnight at 18°C.  Linker was prepared by annealing 5 nmoles each of 
LMPCR.1 (5’-GCGGTGACCCGGGAGATCTGAATTC-3’) and LMPCR.2 (5’-
GAATTCAGATC-3’) in 300 µL 1X ligase buffer, which results in a ds oligo with a 
14 nt ss overhang that can only ligate unidirectionally.  Ligated DNA samples 
were heated at 70°C for 10 min, diluted 5X in dH20 and then assayed for gapdh 
DNA by PCR to adjust DNA input prior to LM-PCR.  The primers 5’Sµ (5’-
GCAGAAAATTTAGATAAAATGGATACCTCAGTGG-3’), Sg3-AP: 5′-
AACATTTCCAGGGACCCCGGAGGAG-3′; and CmuL2: 5′-
CTGCGAGAGCCCCCTGTCTGATAAG-3′ were used in conjunction with linker 
primer (LMPCR.1) to amplify DNA breaks in Sµ, Sγ3, or Cµ respectively.  Three-
fold dilutions of input DNA (0.5, 1.5 and 4.5 µL for Sµ/Cµ LM-PCR, 1.5, 4.5 and 
13.5 µL for Sγ3 LM-PCR) were amplified by HotStar Taq (Qiagen) using a 
touchdown PCR program (28 cycles after touchdown for Sµ LM-PCR and 35 
cycles after touchdown for Sγ3 LM-PCR).  PCR products were electrophoresed 
on 1.25% agarose gels and blotted onto nylon membranes (GeneScreen Plus, 
Perkin Elmer, Waltham, MA).  Blots were hybridized with an Sµ-specific 
oligonucleotide probe (mu probe5’: 5’-AGGGACCCAGGCTAAGAAGGCAAT-3’) 
for 5’ Sµ LM-PCR, or Sγ3-LP: 5′-
GGACCCCGGAGGAGTTTCCATGATCCTGGG-3′ or Cµ: 5′-
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TGGCCATGGGCTGCCTAGCCCGGGACTTCCTG-3′ that had been end-labeled 
with [γ32P]-ATP. Semi-quantitative assessment of DSB frequency was achieved 
by densitometry scanning of autoradiographs, combining all 3 dose titration lanes 
for each set (from one mouse).  For determination of the sites of DSBs, PCR 
products were cloned into pCR4-TOPO (Invitrogen, Carlsbad, CA). 
 
Immunoprecipitation and western blot.  Retrovirus transduced live B cells 
were purified by Lympholyte M floatation.  The live cells were then subjected to 
whole cell extraction.  To make the whole cell extract, 107 cells were incubated in 
100 µl RIPA buffer (25 mM Tris•HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS, 10 mM Tris-Cl pH 8.1, 1 mM EDTA, 1X EDTA–
free protease inhibitor cocktail, 10 mM NaF, 1 mM Na3VO4, 10 µg/ml PMSF) in 
ice for 5 minutes.  The cell lysate was passed through a pipette 15-20 times to 
make a homogeneous mixture.  The mixture was again incubated in ice for 5 
minutes, then centrifuged at 14,000xg for 15 minutes at 4°C to separate the cell 
debris from the protein extracts.  The protein extracts were then quantified by 
Bradford assay.   
 
For immunoprecipitation, the cell lysates were precleared with 75µl of 50% 
coated protein A/G slurry.  The lysates were diluted to 1.4 ml using dilution buffer 
(0.01% SDS, 1.1% Triton-X 100, 1.2 mM EDTA, 16.7 mM Tris-Cl pH 8.1, 167 
mM NaCl, 1X EDTA–free protease inhibitor cocktail, 10 mM NaF, 1 mM Na3VO4, 
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10 µg/ml PMSF in distilled water).  2-4 µg of antibodies were added and 
incubated overnight at 4°C.  Non-specific IgG was used as negative control.  The 
following day, the beads were pelleted by centrifuging at 500Xg. The supernatant 
was carefully removed and discarded without disturbing the bead pellet.  The 
beads were washed once with 1XPBS containing 1X EDTA–free protease 
inhibitor cocktail, 10 mM NaF, 1 mM Na3VO4, 10 µg/ml PMSF, twice with 1XPBS 
containing 150 mM NaCL, 0.1% NP-40, 1X EDTA–free protease inhibitor 
cocktail, 10 mM NaF, 1 mM Na3VO4, 10 µg/ml PMSF. After the third wash, the 
beads were resuspended and boiled for 5 minutes in 50 µL of loading buffer 
containing 300 mM of NaCl.  Then the solution with beads was allowed to cool to 
room temperature, centrifuged at max speed for 2 minutes and the supernatant 
was loaded onto 5-20% gradient protein gel.  Electrophoresis was performed in 
1XHepes buffer (0.1 M Tris, 0.1 M HEPES, 0.1% SDS, pH 8).   
 
After electrophoresis, the protein samples in the gel were transferred onto 
Immobilon-P transfer membrane (size 0.45 µm).  Blots were blocked with 5% 
non-fat milk for two hours, then incubated with 10 ml of the milk containing 2-4 µg 
of antibodies overnight.  The blot is then washed 3 times with 1X wash buffer (1 L 
1XPBS with 250 µL NP-40).  The washed blot is incubated in 10 ml 5% milk 
containing secondary antibodies for 2 hours at room-temperature.  The blot was 
washed 3 times with the 1X wash buffer, and then exposed to X-ray film.  
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Chapter III 
RESULTS 
 
Expression of ΔAID-ER or AID-ER does not alter cell cycle progression or 
cell proliferation. 
To test the role of the AID C terminus in CSR, we expressed full length AID or 
truncated AID lacking the C terminal 10 amino acids by retroviral transduction in 
activated aid-/- mouse splenic B cells. The retroviral constructs encode full-length 
AID or ΔAID (Δ189-198) fused to a FLAG tag and the estrogen receptor (ER) 
(AID-ER and ΔAID-ER, respectively) (34) (Fig 6a).  The fusion protein is followed 
by an internal ribosome entry site (IRES) and a gene encoding enhanced green 
fluorescent protein (EGFP).  This entire construct is flanked by long terminal 
repeats (LTR).  We also prepared a control vector that expressed the ER protein 
but no AID.    
 
The three retroviral constructs (RV-AID-ER, RV-ΔAID-ER or RV-ER) were 
transduced into aid-/- splenic B cells two days after activation with LPS, BlyS, 
and anti-IgD dextran.  The cultures were treated with tamoxifen (4OHT) at the 
time of infection, which induces nuclear localization of ER-tagged proteins, in 
order to allow AID to reach its target.  One day later, transduction efficiency was 
assayed by GFP expression (Fig 6b).  GFP expression in the experiments 
presented in this study varied from ~65-95%.  In the studies reported here, we 
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only include experiments in which the three different retroviruses yielded similar 
GFP expression. Consistent with previous reports, full length AID-ER induces 
~10-fold more IgG1 and IgG3 CSR than ΔAID-ER in aid-/- splenic B cells, as 
shown in the flow cytometry analyses in Fig 6f.  In preliminary experiments, we 
found that nearly all the AID-ER protein is in the nucleus and that the expression 
levels of AID-ER and ΔAID-ER proteins in cells with similar GFP expression are 
quite similar (Fig 6c).  Previously, it was reported that ΔAID-ER is not expressed 
as well as AID-ER in splenic B cells (34).  Perhaps this is because in those 
experiments, cells were cultured for 3 days after viral transduction, whereas we 
assay our experiments one day after transduction. We chose this time because 
there is less cell death on day 1 than on subsequent days.  
 
Since CSR is cell division linked (96), it is important to examine whether the cell 
cycle profiles and cell proliferation rates in cells expressing ΔAID-ER are similar 
to that of cells expressing AID-ER.  We stained cells expressing AID-ER, ΔAID-
ER, or ER with propidium iodide (PI) on day 1 after transduction and examined 
the cell cycle profile of each using flow cytometry.  AID-ER or ΔAID-ER 
expression has no effect on cell cycle progression of aid-/- B cells (Fig 6d).  To 
examine cell proliferation, B cells were stained with PKH26, which binds to the 
cell membrane, prior to activation and transduction with RV-AID-ER, RV-ΔAID-
ER, or RV-ER.  Flow cytometry indicated that cells transduced with the three 
different RV constructs proliferate similarly (Fig 6e).  We also performed CSR 
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assay to make sure that our retroviral constructs behaved similarly to previously 
published results, which showed that CSR was reduced by 80-90% in ΔAID-ER 
expressing cells (Fig 6f).  Western blots of nuclear extracts of B cells expressing 
AID-ER, ΔAID-ER, and ER showed similar nuclear localization of the proteins in 
cells treated with 4OHT at the time of retroviral transduction (Fig 6g). 
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Figure 6 
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Figure 6  Transduction of RV-AID-ER, RV-ΔAID-ER, and RV-ER in aid-/- 
mouse splenic B cells does not alter cell cycle progression or cell 
proliferation.  (a) RV-AID and RV-ΔAID constructs each contain an AID-FLAG-
ER fusion protein gene, an internal ribosome entry site (IRES), a gene encoding 
enhanced green fluorescent protein (EGFP), and a puromycin selection marker.  
These genes are flanked by RV Long Terminal Repeat (LTR) sequences.  RV-
ΔAID has amino acids 189-198 deleted.  (b) Examples of FACS profiles to show 
EGFP (GFP) expression in aid-/- mouse splenic B cells one day after 
transduction with RV-AID-ER, RV-ΔAID-ER, or RV-ER.  (c) Western blot of whole 
cell extracts (WCE) of aid-/- B cells show equivalent expression levels of RV-AID-
ER, RV-ΔAID-ER, and RV-ER in extracts from equal numbers of transduced 
cells.  On the gels, the apparent molecular weight of the AID-ER protein is ~90 
kD.  (d) Cell cycle profiles of aid-/- B cells one day after transduction with RV-
AID-ER, RV-ΔAID-ER, or RV-ER; overlap of the profiles (right most panel) 
demonstrates similar cell cycle profiles.  (e) Cell proliferation profile of aid-/- B 
cells which were stained with PKH26 on day 0, activated for 2 days, then 
transduced with RV-AID-ER, RV-ΔAID-ER, or RV-ER, and harvested 2 days after 
transduction.  Overlapped profiles (right most panel) demonstrate identical 
proliferation. (f) FACS profiles of  CSR assay showing switching to IgG1/IgG3 in 
aid-/- B cells expressing AID-ER, ΔAID-ER, or ER.  Each panel shows viable and 
GFP+ cells, each gate represents PE-IgG1/PE-IgG3 positive cells, as indicated 
within the GFP+ population.  The profiles show ~90% reduction in CSR in ΔAID-
ER compared to that of the AID-ER expressing cells. (g) western blot of Nuclear 
and cytoplasmic fraction of aid-/- B cells expressing AID-ER, ΔAID -ER, or ER 
show similar levels of AID-ER, ΔAID -ER and ER proteins in the nucleus and 
cytoplasm of cells treated with 4OHT at the time of retroviral transduction. 
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AID and UNG bind co-dependently to Sµ DNA dependent upon the AID C-
terminus. 
To begin to explore the function of the C terminus of AID, we asked if ΔAID-ER 
associates with the Sµ region in vivo.  ΔAID -ER has been shown to cause as 
many mutations as AID-ER in the 5’ region of Sµ in cells induced to undergo 
CSR (34).  Also, ΔAID has been found to have equivalent or higher catalytic 
activity than full-length AID in cell-free experiments (87, 97).  We expressed AID-
ER, ΔAID -ER, or ER alone in aid-/- splenic B cells, and performed chromatin 
immunoprecipitation (ChIP) using antibody for ER.  Surprisingly, the ChIP data 
show decreased association of ΔAID-ER with Sµ DNA compared to AID-ER (Fig 
7a).  As anti-ER antibody can precipitate AID-ER, ΔAID -ER, and ER proteins 
equally well (Fig 7b), we conclude that binding of AID-ER to the Sµ region that is 
stable enough to be detected by ChIP depends upon its C terminus.  Since in the 
absence of the C terminus, AID can still induce mutations at Sµ, it is clear that 
this stable association with Sµ is not important for its ability to deaminate Sµ, 
although it might be important for CSR. 
 
Cells expressing ΔAID -ER show an increased proportion of C>T and G>A 
transition mutations relative to C>A and C>G or G>C and G>T transversion 
mutations (34), similar to the phenotype of ung-/- B cells.  This observation 
suggests that AID might associate with UNG via the AID C terminus, and help 
recruit UNG to switch regions.  We asked, therefore, if association of 
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endogenous UNG with Sµ is compromised in cells expressing the C terminal 
deleted AID.  Indeed, ChIP with anti-UNG antibody demonstrated that whereas 
UNG associates with Sµ in aid-/- B cells expressing AID-ER, it is found only at 
background levels in cells expressing ΔAID-ER (Fig 7d).  Neither AID-ER, ΔAID-
ER nor UNG are found at the Cµ region in these cells, which indicates that the 
association is specific for Sµ (Fig 7a,d). 
 
Our finding that binding of UNG to Sµ in vivo depends on the AID C terminus, 
prompted us to ask if the preferential binding of full-length AID to Sµ likewise 
depends upon UNG.  We expressed AID-ER, ΔAID-ER, and ER in aid-/- ung-/- 
splenic B cells and performed ChIP with anti-ER antibody.  Our results clearly 
show that in cells lacking UNG, full length AID-ER does not associate better than 
ΔAID-ER with Sµ (Fig 7a).  Therefore, the ability of full-length AID but not C 
terminal deleted AID to associate with Sµ depends upon the presence of UNG.  
These data suggest that AID and UNG bind co-dependently to the Sµ region in B 
cells undergoing CSR, and that this co-dependently binding depends on the AID 
C-terminus. 
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Figure 7 
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Figure 7  Chromatin immunoprecipitation (ChIP) demonstrates that the C-
terminus of AID is required for recruitment of AID-ER and UNG to Sµ DNA, 
and that UNG is important for recruitment of AID-ER to Sµ .  (a) Anti-ER ChIP 
of extracts from aid-/- splenic B cells expressing AID-ER, ΔAID-ER, or ER shows 
association of AID-ER with Sµ in aid-/- B cells but not in aid-/- ung-/- cells, and 
not at Cµ in either genotype.  ChIP was analyzed by real-time PCR.  Means 
+SEM of 3 or more ChIPs for Sµ and Cµ are shown.  (b) Western blot of IP 
performed using anti-ER antibody and normal IgG (negative control) on WCE of 
aid-/- splenic B cells expressing   AID-ER, RV-ΔAID-ER, or RV-ER shows 
equivalent expression levels of RV-AID-ER, RV-ΔAID-ER and RV-ER.  Msh2 is 
the loading control in b.  Percent of cells, which express GFP in each culture, is 
shown at the bottom of the corresponding lane.  (c) Western-blot of WCE of aid-/- 
ung-/- splenic B cells expressing RV-AID-ER, RV-ΔAID-ER, or RV-ER.  GAPDH 
is the loading control (left panel). Western-blot of nuclear extract of aid-/- ung-/- 
splenic B cells expressing RV-AID-ER, RV-ΔAID-ER, or RV-ER.  Non-specific 
bands are the loading control (right panel)  (d) Anti-UNG ChIP of extracts from 
aid-/- splenic B cells expressing RV-AID-ER, RV-ΔAID-ER, or RV-ER, showing 
specific association of UNG with Sµ in RV-AID-ER but not RV-ΔAID-ER 
expressing aid-/- splenic B cells. Means+SEM of 3 or more ChIPs for Sµ and Cµ 
are shown. (e) Anti-PolII ChIP shows specific association of PolII with Sµ in RV-
AID-ER, RV-ΔAID-ER, and ER expressing aid-/- splenic B cells. The differences 
among the three are not significant.  Means+SEM of 3 ChIPs for Sµ and Cµ are 
shown. 
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AID and Msh2-Msh6 bind co-dependently with Sµ DNA dependent upon the 
AID C-terminus. 
The mismatch repair (MMR) heterodimer Msh2-Msh6 binds to U:G mismatches 
that result from AID activity (98), and the specificity of AID-induced mutations at 
G:C bp is altered in msh6-/- cells (28, 30).  We asked if association of 
endogenous Msh2-Msh6 with Sµ in vivo depends upon the C terminus of AID.  
ChIP for Msh2 and for Msh6 in aid-/- B cells expressing AID-ER, ΔAID-ER, or ER 
demonstrated that both Msh2 and Msh6 associate with Sµ in cells expressing 
full-length AID-ER, but not significantly above background when expressing 
ΔAID-ER or ER (Fig 8a).  Binding of Msh2 and Msh6 is not detected at the Cµ 
region (Fig 8b), in agreement with our finding that AID-ER binds with Sµ and not 
Cµ.  
  
We next asked if binding of full-length AID to Sµ in vivo might depend upon these 
MMR proteins by expressing the RV constructs in aid-/-msh2-/- and in aid-/-msh6-/- 
cells.  Indeed, we found that in the absence of Msh2 or Msh6, AID-ER does not 
bind better than ΔAID-ER to the Sµ region, and the binding was at background 
levels  (Fig 8c). In fact, we detected no binding above background of AID-ER in 
aid-/-msh2-/- cells.  This is not due to differential expression of the AID proteins, 
as the levels of AID-ER and ΔAID-ER are similar in B cells from both aid-/- msh2-
/- and aid-/- msh6-/- mice (Fig 8d).  Together with the results showing reduced 
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binding of Msh2-Msh6 to Sµ in cells expressing ΔAID-ER, these data suggest 
that AID binds co-dependently with Msh2-Msh6 to the Sµ region and that this co-
dependent binding depends on the C terminus of AID. To reconcile these results 
with published results indicating that AID and ΔAID have similar abilities to 
generate mutations in the Sµ region (34), we hypothesize that co-dependent 
binding of AID with UNG and Msh2-Msh6 stabilizes the binding of AID to Sµ, thus 
allowing the binding to be detected by ChIP.  This increased stability does not 
appear necessary, however, for the deamination activity of AID. 
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Figure 8 
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Figure 8  ChIP demonstrates that the C-terminus of AID is important for 
recruitment of Msh2-Msh6 to Sµ DNA, and that Msh2-Msh6 is important for 
binding of AID-ER to Sµ .  (a) Anti-Msh2 and anti-Msh6 ChIP of extracts from 
aid-/- splenic B cells expressing RV-AID-ER, RV-ΔAID-ER, or RV-ER shows 
association of Msh2 and Msh6 with Sµ, but not Cµ (b), in aid-/- B cells expressing 
RV-AID-ER but not in cells expressing RV-ΔAID-ER.  Means+SEM of 3 or more 
ChIPs for Sµ are shown. (c) Anti-ER ChIP of extracts from aid-/-, aid-/-msh2-/- 
and aid-/-msh6-/- splenic B cells expressing RV-AID-ER, RV-ΔAID-ER, or RV-
ER.  One ChIP was done as a positive control in aid-/- B cells.  Means of two or 
more ChIPs for Sµ and Cµ are shown for aid-/-msh2-/- and aid-/-msh6-/- B cells. 
Error bars indicate either the range (when 2 ChIPs performed).  (d) Western blots 
of WCE (top left panel) and nuclear extract (top right panel)  from aid-/-msh2-/- 
and aid-/-msh6-/- (bottom left and bottom right panel respectively) mouse splenic 
B cells expressing RV-AID-ER, RV-ΔAID-ER, or RV-ER, show equivalent levels 
of expression of RV-AID-ER and RV-ΔAID-ER as well as equivalent levels of 
nuclear localization in the cells treated with 4OHT at the time of retroviral 
transduction.  GAPDH is the loading control in WCE and non-specific band in 
nuclear extract.   
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The C terminus of AID is required for the function of MMR proteins during 
CSR. 
CSR is reduced by ~50-70% in MMR-deficient B cells (1, 27, 28, 94, 99).  As we 
found that the co-dependent binding between AID and the Msh2-Msh6 
heterodimer at Sµ depends upon the AID C terminus, we next asked if the C 
terminus of AID is important for the function of MMR during CSR.  Although ΔAID 
deaminates dC’s in Sµ, thereby producing the U:G substrate for MMR, we 
hypothesized that recruitment of Msh2-Msh6 by AID is essential for CSR, and 
that in cells expressing ΔAID-ER, deficiencies in Msh2 or Msh6 proteins will not 
reduce CSR efficiency relative to MMR-sufficient cells.  To test this hypothesis, 
we examined CSR to IgG1 and IgG3 in aid-/-msh2-/- and in aid-/-msh6-/- B cells 
transduced with the three RV constructs (Fig 9).  In cells expressing full-length 
AID, CSR was reduced by 45-70% by Msh2 or Msh6-deficiency, consistent with 
results in MMR-deficient cells expressing endogenous AID.  Although switching 
to IgG1 in aid-/- B cells expressing ΔAID-ER is reduced by ~90% compared to 
that of cells expressing AID-ER, it is not further reduced by deficiencies in Msh2 
(Fig 9a,b, upper panels) or Msh6 (Fig 9c,d, upper panels).  Similarly, switching to 
IgG3 in ΔAID-ER-expressing aid-/- B cells is reduced by ~90% relative to AID-
ER-expressing aid-/- B cells, but not further reduced in aid-/- msh2-/- B cells (Fig 
9a,b, lower panels) or in aid-/- msh6-/- B cells (Fig 9c,d, lower panels).  
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We conclude from these data that the contributions of Msh2 and Msh6 to CSR 
are abolished in B cells expressing ΔAID-ER.  As C terminal deleted AID is an 
active deaminase and induces Sµ mutations, this is not due to the lack of 
substrates for Msh2-Msh6 in Sµ in cells expressing ΔAID-ER.  These results also 
indicate that despite being over-expressed, AID-ER behaves similarly to 
endogenous AID as optimal CSR depends upon MMR.  Most interestingly, the 
data suggest that the ability of the AID C terminus to directly or indirectly recruit 
MMR proteins to the Sµ region is important for the function of MMR during CSR.   
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Figure 9
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Figure 9   Msh2-Msh6 proteins increase CSR in cells expressing AID-ER but 
not in cells expressing ΔAID-ER.  (a) FACS results for one experiment 
showing CSR to IgG1 and IgG3 (indicated on left) in aid-/- and aid-/-msh2-/- 
splenic B cells expressing RV-AID-ER, RV-ΔAID-ER, or RV-ER.  Each panel 
shows viable cells that are GFP positive, and each gate shows PE-IgG1 or PE-
IgG3 stained cells within the GFP+ population.  (b) Compilation of CSR results in 
aid-/- and aid-/- msh2-/- cells expressing RV-AID-ER, RV-ΔAID-ER, or RV-ER 
showing the mean+SEM for 9 cultures, 3 cultures per mouse.  (c) FACS results 
showing CSR to IgG1 and IgG3 (indicated on left) in aid-/- and aid-/-msh6-/- 
splenic B cells expressing AID-ER, ΔAID -ER, or ER.  Similar to a. (d) 
Compilation of CSR results in aid-/- and aid-/- msh6-/- cells expressing AID-ER, 
ΔAID-ER, or ER showing the mean+SEM for 9 cultures, 3 cultures per mouse. 
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The dominant negative effect of ΔAID-ER depends upon the presence of 
MMR proteins.  
Patients heterozygous for C terminal deleted AID have hyper-IgM syndrome 
(HIGM2), suggesting that this mutant is a dominant negative mutant, and 
consistent with the known ability of the C terminal deleted AID to dimerize with 
full-length AID (36).  We asked whether ΔAID-ER has a dominant negative effect 
when expressed in mouse splenic B cells with normal endogenous AID levels.  
We compared IgG1 and IgG3 as a function of GFP mean fluorescence intensity 
(MFI), as an indicator of AID expression levels.  Increasing expression of AID-ER 
results in increased IgG1 CSR relative to cells expressing endogenous AID 
levels (GFP-negative) (Fig 10a, left panel).  However, increasing doses of ΔAID-
ER does not increase CSR to IgG1, and at the highest expression level results in 
decreased CSR.  CSR to IgG3 does not increase significantly with increasing 
expression of AID-ER in WT B cells, but decreases dramatically with increasing 
expression of ΔAID -ER (Fig 10a, middle panel).  These data demonstrate that 
ΔAID-ER has a dominant negative effect on CSR in WT mouse B cells.   
 
We considered two possibilities to explain the dominant negative effect of ΔAID.  
Its ability to dimerize with endogenous AID might sequester endogenous AID 
from Sµ.  Alternatively, the heterodimer might bind Sµ but prevent association of 
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UNG and/or MMR proteins with full-length AID at Sµ.  Either mechanism would 
inhibit CSR.  To examine these possibilities, we performed ChIP using anti-ER 
antibody to determine if ΔAID -ER associates with Sµ in cells expressing 
endogenous AID.  WT B cells transduced with ER were used as negative 
controls.  The ChIP results with anti-ER antibody indicate that ΔAID -ER is 
actually recruited better than AID-ER to the Sµ region in AID-sufficient cells 
(p=0.005)(Fig 10a, right panel).   
 
We hypothesized that the dominant negative effect observed in WT B cells 
expressing ΔAID -ER might be due to the inability of heterodimers of ΔAID -ER 
and endogenous WT AID to recruit CSR-specific proteins, such as UNG and/or 
Msh2-Msh6.  If this is correct, then the dominant negative effect should be 
reduced in MMR-deficient B cells relative to that in WT B cells.  To test this, we 
expressed AID and Δ AID in AID-sufficient msh2-/- or mlh1-/- B cells and 
analyzed CSR by flow cytometry.  Expression of AID-ER in WT B cells increases 
switching to IgG1 and IgG3 relative to cells expressing the negative control ER 
(Fig 10b-e).  However, CSR is significantly lower in WT cells expressing ΔAID-
ER than in cells expressing ER (Fig 10c, e).  This illustrates the dominant 
negative effect of ΔAID-ER in WT B cells.  Interestingly, ΔAID-ER does not have 
a dominant negative effect in msh2-/- or mlh1-/- cells. These results taken 
together with the ChIP results suggest that deletion of the C-terminus of AID 
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reduces the ability of endogenous AID to recruit MMR proteins to Sµ, thereby 
preventing the contribution of MMR to CSR.  
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Figure 10 
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Figure 10   ΔAID-ER inhibits recruitment of MMR proteins to Sµ by 
endogenous AID, thereby resulting in a dominant negative effect on CSR.   
(a) IgG1 and IgG3 switching in aid+/+ mouse splenic B cells expressing 
increasing doses of AID-ER or ΔAID-ER, as assayed by GFP expression 
(fluorescence intensity), are increased or inhibited, respectively.  Cells 
expressing more GFP express more AID or ΔAID (data not shown).  Each data 
point on the curve is the mean %IgG1 or %IgG3+SEM of 3 cultures. Right panel 
shows an anti-ER ChIP assay of WT splenic B cells expressing AID-ER, ΔAID-
ER, or ER.  (b) FACS results for one representative CSR experiment comparing 
the dominant negative effect of ΔAID-ER in WT and msh2-/- B cells (expressing 
endogenous AID).  The FACS plots show only viable and GFP positive cells, the 
gates represent PE-IgG1/PE-IgG3 positive cells within the GFP+ populations as 
indicated.  (c) Compilation of CSR results(represented in b), CSR is relative to 
AID-ER expressing WT B cells for 6 cultures, 3 cultures per mouse. Error bars 
represent SEMs. (d) FACS results for one experiment comparing the dominant 
negative effect of ΔAID-ER in WT and mlh1-/- B cells.  (e) Compilation of CSR 
assays(represented in d), CSR is relative to AID-ER expressing WT B cells for 6 
cultures, 3 cultures per mouse. Error bars represent SEMs.  Lower panel: 
percent reduction in CSR in RV-ΔAID-ER expressing cells relative to RV-ER 
(dominant negative effect) in WT vs mlh1-/- splenic B cells for IgG1 and IgG3 
CSR.  
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AID and UNG do not interact in vitro. 
In order to test whether AID and UNG interact in vitro, I performed GST pull-
down with N-terminally GST tagged UNG. I used an in vitro 
transcription/translation kit to prepare AID-ER, ΔAID -ER, ER, GST, and GST-
UNG (N-terminal tagged) in vitro.  I performed numerous control experiments, 
which indicated very efficient production of the above-mentioned proteins.  The 
GST-UNG and GST alone pull-down assay yielded the same results, showing no 
preferential binding of full length AID-ER relative to ΔAID-ER or ER.  Control 
experiments demonstrated that both GST and GST-UNG were pulled down 
efficiently by glutathione beads (fig 11b,d).  I conclude that AID and UNG do not 
directly interact in vitro (fig 11a,c).  
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Figure 11
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Figure 11  In vitro translated AID and UNG do not interact in vitro. (a) 
Immunoblot probed with anti-ER antibody shows that GST is unable to pull down 
in vitro translated AID-ER, ΔAID-ER or ER. (b) Immunoblot of aliquots from GST 
pull-down probed with anti-GST antibody shows efficient pull down of GST by 
glutathione beads. (c) Immunoblot probed with anti-ER antibody shows that 
GST-UNG is unable to pull down AID-ER, ΔAID -ER or ER in vitro. (d) 
Immunoblot of aliquots from GST-UNG pull-down probed with anti-GST antibody 
shows efficient pull down of GST-UNG by glutathione beads. 
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ΔAID-ER induces S region DSBs in aid-/- B cells. 
DSBs are an essential intermediate in CSR, and are dependent upon AID, UNG 
(42), and MMR (12). Our findings that ΔAID-ER binds less well to Sµ than does 
AID-ER, and that ΔAID -ER does not recruit UNG or MMR suggest that there 
might be fewer Sµ DSBs in vivo in cells undergoing CSR.  To address this 
hypothesis, we performed ligation-mediated (LM)-PCR to analyze Sµ DSBs in 
aid-/- B cells expressing AID-ER, ΔAID-ER, or ER.  As expected, uninfected WT 
B cells showed abundant DSBs in Sµ and Sγ3 regions while aid-/- B cells, 
uninfected or infected with control RV-ER showed very few S region DSBs (Fig 
12a).  We also performed LM-PCR on GFP-negative cells FACS-sorted from RV-
infected populations and, as expected, found very few S region DSBs (Fig 12a).  
Surprisingly, aid-/- cells expressing either AID-ER or ΔAID-ER contain abundant 
S region DSBs.  We quantified the DSBs using densitometry, which revealed that 
ΔAID-ER induced more DSBs (~1.5 fold) than AID-ER in both Sµ and Sγ3 
regions of aid-/- B cells (Fig 12b).  As shown in Fig 12a, the GFP expression 
among the different cell populations used for LM-PCR was similar, suggesting 
that the expression of AID and ΔAID was similar in these cultures.  The finding 
that DSBs are at least as numerous in ΔAID–ER- relative to AID-ER-expressing 
cells is surprising because both UNG and MMR are important for DSBs in S 
regions, and these proteins do not appear to be recruited in cells expressing 
ΔAID–ER.  These data clearly indicate that the block in CSR due to lack of the 
AID C terminus occurs downstream of S region DSB formation. 
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To determine whether there is any difference between the DSB sites in cells 
expressing full length or C terminal deleted AID, we cloned and sequenced the 
LM-PCR products.  The sites of DSBs in Sµ of AID-ER or ΔAID-ER expressing 
aid-/- B cells are indistinguishable from each other and from those in WT B cells 
expressing endogenous AID (10, 42) (Fig 12c).  Most of the DSBs occur at G:C 
bp, and preferentially at AID (WRC/GYW) target hotspots.  These data suggest 
that deletion of the AID C terminus does not alter the mechanism or the ability of 
AID to generate DSBs in the Sµ region.  Thus, although the weak binding of 
ΔAID-ER relative to AID-ER to Sµ is sufficient to induce normal frequencies of 
deamination and DSBs in S regions, it appears insufficient to direct the S region 
DSBs toward proper CSR. 
 
In conclusion, these data reveal that the C-terminus of AID is involved in 
recruitment of UNG and Msh2-Msh6 to Ig Sµ regions, and that this recruitment is 
important for the function of Msh2-Msh6 in CSR.  Although both UNG and MMR 
have been demonstrated to be important for DSB formation during CSR, our 
results indicate that the AID C terminus is not required for Sµ or Sγ3 DSBs.  Our 
results support the hypothesis that in addition to deamination of dCs, leading to 
DSBs, AID has functions downstream of generation of DSBs that are required for 
CSR, and that this involves specific recruitment of UNG and MMR to S regions.  
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Figure 12 
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Figure 12  ΔAID-ER is proficient in inducing Sµ  and Sγ3 DSBs during CSR.  
(a) Upper panels: Southern blots showing LM-PCR results for aid-/- splenic B 
cells expressing AID-ER, ΔAID-ER, or ER cultured to switch to IgG3.  LM-PCRs 
performed on DNA from WT and aid-/- B cells were used for positive and 
negative controls, respectively.  Lower panels show LM-PCR results for GFP-
negative cells from the same aid-/- cultures shown in the upper panels, 
demonstrating that DSBs depend on AID and ΔAID. GAPDH indicates the PCR 
for gapdh genes, used as an internal template loading control.  3-fold dose 
titrations were assayed.  Mean GFP expression levels+SEM for AID-ER, ΔAID-
ER and ER cultures in 3 independent experiments (different mice) are shown in 
the histograms.  (b) Quantitation of 3 LM-PCR experiments by densitometry of 
autoradiographic films, scanning all 3 lanes for each genotype; histograms 
represent relative means+SEM.  (c) Tabulation of sites of blunt DSBs obtained 
from LM-PCR products, comparing results from cells expressing endogenous 
AID (10).  
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Chapter IV 
DISCUSSION 
 
It is intriguing that deamination of S-regions by AID is not the entire role of AID 
during CSR.  Although ΔAID appears to induce normal levels of deamination in 
the S-regions when B cells are activated to switch, the deamination is not 
translated into a normal levels of CSR (34).  This phenomenon makes it quite 
clear that AID has a larger role during CSR than simply deamination.  This 
prompted me to study the role of AID in steps of CSR that are downstream of 
deamination. 
 
Previous studies (observation in humans) (36) and my observations in this study 
(in mouse) have proved that ΔAID inhibits CSR when expressed in WT B cells.  
The dominant negative effect of ΔAID is a clear indication that ΔAID interferes 
with full length AID’s ability to support CSR, which I speculate to require 
interactions between AID and other proteins required for CSR.  The interaction 
between AID and other CSR-specific proteins probably not only promotes 
efficient completion of CSR, but also channels the AID protein away from its 
potent genotoxic property, for example denying the catalytic site of AID to access 
the DNA by steric hinderance.  AID is an essential protein for the humoral 
immune response, yet it’s activity is highly genotoxic.  Hence, AID protein and B 
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cells must have evolved to balance the necessary activity and genotoxic activity 
of AID. In support of this hypothesis, it is clear from previous studies that B cells 
have evolved to allow high levels of AID expression only upon immunization.  B 
cells have evolved to compartmentalize AID protein in the cytoplasm by making 
the nuclear localization signal weak (32), and nuclear export signal strong (39). 
They have also evolved to make sure that the deamination activity is potentiated 
by post-translation modification such as phosphorylation of S38; only a small 
percentage of nuclear AID is phosphorylated (72-74).  In addition, cells have 
evolved to rapidly ubiquitinate and degrade nuclear AID; nuclear AID is three 
times less stable than cytoplasmic AID (76).    
 
It is clear from my data that a transient interaction (undetectable by ChIP) of AID 
with DNA is adequate to generate mutations at the S-region; hence, any longer 
interaction of AID protein with DNA would be highly detrimental.  Hence, keeping 
in mind the potent deamination activity of AID and the need for the AID activity to 
be negatively regulated, I thereby speculate that AID has evolved to interact with 
other proteins that are necessary for CSR to not only dampen the deamination 
activity of AID, but also to localize the deletional recombination to the Igh locus.  
Deletional recombination is essential for CSR but it is highly detrimental to the 
cells if it takes place between Igh and another locus or among other loci. AID 
induces significant collateral damage during CSR, as evidenced by AID induced 
DNA breaks in other loci (100-103).  However, to ensure that the deletional 
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recombination among those loci doesn’t take place, cells might have evolved to 
employ AID itself to form a CSR specific recombination complex.  Hence, AID 
might have evolved to nucleate a CSR specific complex by co-dependent binding 
of AID with other proteins necessary for CSR at the Igh locus. 
 
To test this hypothesis, I immunoprecipitated (IP) AID-ER protein, expressed in B 
cells with the help of retroviral transduction, with anti-ER antibody and tested for 
co-IP of proteins that are necessary for CSR such as UNG and Msh2/Msh6.  The 
IP however did not yield any positive co-IP.  Unsatisfied with this revelation, I 
decided to find out whether AID protein intrinsically interacts with UNG protein.  
For this end, I utilized in vitro transcribed and translated AID-ER, ΔAID-ER, ER, 
GST and GST-UNG (N-terminal GST) proteins; the ITT yielded copious amounts 
of the proteins.  The GST pull down of the UNG protein revealed that AID and 
UNG do not have intrinsic ability to interact with each other. 
 
Since I was unable to detect protein-protein interactions among AID and other 
CSR specific proteins by IP, I decided to dissect the protein-DNA-protein 
interaction by ChIP assay.  In this study, I have demonstrated that AID binds co-
dependently with both UNG and Msh2-Msh6 to the Ig Sµ region in B cells, and 
that the co-dependent binding requires the C terminal 10 amino acids of AID.  No 
binding of AID, UNG or Msh2-Msh6 was detected at the Cµ gene. The 
associations between AID and UNG and between AID and Msh2-Msh6 are 
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detected when AID is localized on the Sµ region; I was not able to detect binding 
in the absence of DNA.  The interaction might be direct or indirect.  Interestingly, 
we found that the MMR proteins Msh2 and Mlh1 do not contribute to CSR in cells 
expressing C terminal deleted AID, indicating that the ability of AID to recruit 
MMR proteins to Sµ is important for CSR.  We also showed that ΔAID is a 
dominant negative mutant, most likely due to its ability to dimerize with full-length 
AID and to prevent recruitment of Msh2-Msh6, and perhaps other proteins, to the 
Sµ region.  The C terminal deletion mutant might also prevent recruitment of 
UNG by endogenous full-length AID, but since CSR is nearly abolished in ung-/- 
cells (6, 12), we were unable to monitor this dominant negative effect 
functionally. 
   
It is puzzling that there are at least as many Sµ DSBs, if not more, in cells 
expressing ΔAID as in cells expressing full-length AID, despite lower recruitment 
of AID, UNG and MMR.  Sµ region DSBs have also been observed in HIGM 
patients with C terminal deletions of AID (104).  Considerable evidence indicates 
that MMR is important for conversion of SSBs to DSBs in S regions during CSR 
(11, 12, 105).  In its absence DSBs appear to only form from SSBs that are near 
on opposite strands.  The observed DSBs in ΔAID-expressing cells might be due 
to such nearby SSBs.  I hypothesize that the slightly increased Sµ DSBs and 
ablation of CSR in cells expressing C terminal deleted AID are due to impaired 
downstream DNA repair and/or recombination.  Unresolved or inefficient joining 
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of DSBs could cause accumulation of S region DSBs, and also could cause 
increased risks of DNA translocations, carcinogenesis, and/or cell death. In fact, 
ΔAID-ER-expressing B cells have a higher frequency of chromosomal 
translocations than cells expressing AID-ER (106).   
 
Chromosomal translocations have been shown to be mediated by 
microhomology-mediated end joining (107), a non-classical form of NHEJ in 
which recombination is mediated by short microhomologies between the two 
recombining sequences.  In addition, B cells with mutations in DNA repair genes 
involved in recombination of S region breaks often show increased lengths of 
junctional microhomology (108). Deficiencies in some MMR proteins also 
increase junctional microhomology (108-110).  Interestingly, it was recently found 
that Sµ-Sα junctions from two human patients expressing AID with C terminal 
deletions show highly significantly increased junctional microhomology (111).  
These results suggest that the AID C terminus is involved in the recombination 
step during CSR and directs S region DSBs towards NHEJ.   
 
Interaction of AID with UNG and MMR might direct S region DSBs towards 
properly regulated CSR.  AID-dependent Sµ DSBs are only observed during G1 
phase in normal splenic B cells undergoing CSR, indicating that the DBS are 
introduced, recombined and repaired during G1 phase (12, 43).   MMR 
associates with the replication machinery and corrects nucleotides mis-
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incorporated due to DNA polymerase errors (13, 112).  UNG is important for 
removal of dU incorporated instead of dT during replication, and in both primary 
fibroblasts and HeLa cells UNG is expressed at much higher levels during S 
phase than during G1 or G2 phases (113, 114).  However, in splenic B cells 
induced to undergo CSR, UNG is slightly more highly expressed in G1 phase 
than in S phase, and is clearly important for excision of dUs due to deamination 
by AID (12, 42).  Perhaps UNG is stabilized by binding to AID.  It is possible that 
if UNG and MMR are not specifically recruited to Sµ during G1 phase, they might 
only be available at S regions during S phase, thus creating DSBs in S phase.  
During DNA replication, DSBs cause stalling of DNA polymerase and collapse of 
replication forks, which could result in unrepaired DSBs, increased 
translocations, and greatly reduced CSR.  
 
The binding of UNG and MMR to AID might be indirect and occur via other 
proteins.  AID has been shown to interact with several proteins.  Protein kinase A 
(PKA), which phosphorylates AID at S38, is specifically localized at Sµ regions 
during CSR, and might participate in a PKA-RPA-AID complex (2, 85).  
Phosphorylation of AID at S38 is required for interaction with RPA and for CSR 
(71, 86), but it is possible that the AID C terminus is also involved.  Interestingly, 
RPA32 has been shown to interact with UNG by the yeast two-hybrid assay (88).  
Also, a recent publication reported that the C-terminus of AID interacts with the 
14-3-3 adaptor protein complex and that this interaction is important for 
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recruitment of AID to S regions (78).  Deficiency in 14-3-3 protein components 
results in a 50% decrease in CSR.  Since the ΔAID-ER mutant induces as many 
Sµ mutations as AID-ER, the recruitment by 14-3-3 of AID itself is not necessary 
for the ability of AID to deaminate Sµ.  It is possible, however, that 14-3-3, when 
bound to AID, is important for recruiting UNG and MMR proteins to Sµ.   
 
UNG and MMR proteins might help recruit other proteins involved in subsequent 
repair steps during CSR.  For example, Msh2 and Msh6 have been found in a 
large complex of DNA repair proteins in HeLa cells, termed BASC, which also 
includes Mre11-Rad50-Nbs1 (MRN).  MRN binds DSBs induced by AID and is 
known to be important for CSR (1, 115, 116).  UNG has been found in a complex 
in HeLa cells that contains proteins involved in base excision repair, including 
APE1, XRCC1, DNA polymerase β, PCNA, and DNA ligase (117).  APE1 is 
important for CSR, and is involved in converting AID-induced lesions to DNA 
breaks (10). DNA Pol β binds S regions, decreases the numbers of Sµ DSBs, 
and inhibits CSR (118). However, it is difficult to understand how these proteins 
would direct the DSBs toward proper S-S recombination.  Another possibility is 
suggested by the findings in over-expression experiments that AID binds DNA-
PKcs, dependent upon the AID C terminus (79), and that Msh2-Msh6 binds to 
Ku70-Ku80 (119).  As Ku is important for directing DNA breaks towards NHEJ, it 
is possible that in addition to its role in converting SSBs to DSBs, MMR 
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associated with the AID C terminus is involved in recruiting DNA-PK-Ku proteins 
to sites of AID-induced DSBs.  
 
Here I propose a model for the initiation of CSR that incorporates my new results 
(Fig 13).  After immunization, transcription through S-region occurs to generate 
ssDNA substrate for AID.  AID is induced and a minimal amount is translocated 
into the nucleus, a portion of which is phosphorylated at S38, which allows AID to 
interact with RPA32, allowing it to bind more strongly to DNA and making its 
deamination activity more potent.  The phosphorylated form has been shown to 
be located preferentially in the chromatin fraction (72-74). Meanwhile AID 
interacts with 14-3-3 adaptor proteins, which altogether promote recruitment of 
UNG and MMR protein to the S regions, to form a protein complex.  Additional 
DNA repair proteins might be recruited.  I propose that this complex is 
responsible for further steps required for CSR, eventually resulting in regulated 
and proper S-S recombination. 
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Figure 13 
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Figure 13 Model for CSR complex assembly. After the activation of B cells via 
immunization of infection, transcription through donor and acceptor S-regions 
take place and AID is expressed.  AID and (DNA dependent protein kinase A) 
PKA are recruited on the S-region independent of each other. PKA then 
phosphorylates AID in S38, which promotes AID interaction with RPA32. AID-
RPA32 interaction DNA binding as well as catalytic activity of AID. This complex 
is deamination competent.  Then AID interacts with 14-3-3 adaptor protein in 
AID-C-terminus dependent manner, which stabilizes AID-DNA complex. Then 
UNG and MMR proteins are also recruited into this complex in the AID-C-
terminus dependent manner as well. This super complex is not needed for DSB 
during CSR however, it is essential for one or more steps that lies downstream of 
DSB formation step. 
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Future directions 
 
To further solidify the idea of co-dependent binding, one could perform some 
more control experiments such as ChIP with anti-UNG antibody in MMR deficient 
B cells and vice versa.  It is also important to test whether other DNA repair 
factors demonstrate AID-dependent co-dependent binding with S-regions.  This 
can be accomplished by ChIP as was done in this study.  This will require 
generating various DNA repair and AID double deficient mice.  
 
Although it is clear that co-dependent binding of AID-UNG-MMR to the Sµ region 
is important for CSR, it is also clear that this co-dependent interaction among the 
proteins is not essential for the deamination step nor the DSB formation step of 
CSR.  Hence, it is important to dissect the steps downstream of both deamination 
and DSBs during CSR.  In order to address whether the NHEJ/DNA repair step 
of CSR is compromised in ΔAID expressing cells, one can try to rescue CSR in 
ΔAID expressing cells by, for example, homologous recombination.  This can be 
accomplished by cloning homologous recombination cassettes containing AID 
hotspot motifs (WRC) into a donor and acceptor S region and testing whether the 
CSR can be rescued by the cassettes in ΔAID expressing cells.  
 
In order to test whether a homologous recombination cassette can rescue CSR 
in ΔAID expressing aid-/- mouse B cells, a knock-in (KI) mouse can be created in 
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which Sµ and Sγ3 regions are replaced by homologous recombination cassettes.  
These cassettes should contain AID hotspots so that AID can introduce 
mutations to initiate DSB formation process. The KI-mice can be then crossed 
with aid-/- mice to generate KI X aid-/- mice.  Then AID-ER, ΔAID-ER or ER can 
be expressed in these KI X aid-/- mouse splenic B cells with the help of retroviral 
transduction.  The phenotype of the transduced B cells can then be evaluated by 
CSR assay as we have done in this study.  If the presence of homologous 
recombination cassettes in the B cells rescue CSR in ΔAID-ER expressing aid-/- 
B cells, then it would mean that AID protein is important for carrying out 
recombination step of CSR but Δ AID is incompetent in carrying out the 
recombination step.  If the homologous recombination cassette doesn’t rescue 
the CSR, then it could mean that ΔAID is probably incompetent in the CSR step 
that is upstream of recombination step, which is not yet characterized.   
 
It is not clear what roles UNG and MMR proteins might have during the CSR 
steps downstream of the DSB formation.  It is possible that the interaction of 
these proteins with AID might furnish these proteins with non-traditional roles in, 
for example, locus specific recombination.  Hence, it is important to develop 
assays that can dissect the roles of UNG and MMR proteins in the CSR steps 
downstream of DSB formation.  And it would be very important to develop 
another assay to understand the biochemical basis of their roles in these 
processes.  
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